Search
for
Sort by
Research 151–180 of 1000+
- Finasteride: the first 5 alpha-reductase inhibitor.
- Finasteride and the 5-Alpha Reductase Inhibitors
- 0192 Estrogenic effects of 5-alpha-reductase inhibitors in male androgenetic alopecia patients
- Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
- Abietic Acid from Resina Pini of Pinus Species as a Testosterone 5.ALPHA.-Reductase Inhibitor
- Relative efficacy of minoxidil and 5-alpha-reductase inhibitors in the treatment of male androgenetic alopecia: protocol for a network meta-analysis study
- Studies on Neurosteroids XXV. Influence of a 5.ALPHA.-Reductase Inhibitor, Finasteride, on Rat Brain Neurosteroid Levels and Metabolism
- Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism
- Review of the Efficacy of Topical 5-Alpha Reductase Inhibitors for the Treatment of Androgenetic Alopecia
- Re: A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Post-Finasteride Syndrome
- Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
- Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-Blockers vs 5-Alpha Reductase Inhibitors
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men
- The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness
- Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
- Quality-of-life changes in women with female androgenetic alopecia treated with a methylsulfonylmethane-containing 5-alpha-reductase inhibitor: a clinical practice study
- Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
- Novel 5α-Reductase Inhibitors: Synthesis, Structure−Activity Studies, and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids
- Synthesis, Biological Evaluation and Molecular Docking of Avicequinone C Analogues as Potential Steroid 5α-Reductase Inhibitors
- Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids
- Synthesis and Biological Evaluation of 4-(4-(Alkyl-and Phenylaminocarbonyl)benzoyl)benzoic Acid Derivatives as Non-steroidal Inhibitors of Steroid 5α-Reductase Isozymes 1 and 2
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review
- 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)